All In Biotech

NDA 020886 · Advanz Pharma

Panretin

Alitretinoin · Topical · Retinoid

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Nov 17, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1999

Feb 2, 1999

Approved uses

1

Original approval plus efficacy supplements

Registered trials

19

10 Phase 3, 0 recruiting

FAERS reports

119

104 serious, 5 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 25, 2025.

1.1 Kaposi’s Sarcoma PANRETIN GEL is indicated for topical treatment of cutaneous lesions in adults with AIDS related Kaposi’s sarcoma (KS). Limitations of Use: PANRETIN GEL is not indicated when systemic anti-KS therapy is required (including more than 10 new KS lesions in the prior month, symptomatic lymphedema, symptomatic pulmonary KS, or symptomatic visceral involvement) [see Clinical Studies ( 14.1 )] . PANRETIN GEL is a retinoid indicated for the topical treatment of cutaneous lesions in adults with AIDS-related Kaposi’s sarcoma (KS). Limitations of Use : PANRETIN GEL is not indicated when systemic anti-Kaposi’s sarcoma therapy is required.

Mechanism: Alitretinoin (9-cis-retinoic acid) is a naturally occurring endogenous retinoid that binds to and activates all known intracellular retinoid receptor subtypes (RARα, RARβ, RARγ, RXRα, RXRβ and RXRγ). Once activated these receptors function as transcription factors that regulate the expression of genes that control the process of cellular differentiation and proliferation in both normal and neoplastic cells. Alitretinoin inhibits the growth of Kaposi’s sarcoma (KS) cells in vitro.

Therapeutic areas: Ophthalmology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 2, 1999 Original approval · Type 1 - New Molecular Entity · priority review LabelReviewLetter
1 products under this application
  • PANRETIN · ALITRETINOIN EQ 0.1% BASE · GEL, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Alitretinoin" as an intervention, any sponsor and status, largest first.

All 19 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use23
  • drug ineffective22
  • drug intolerance9
  • headache9
  • hypercholesterolaemia8
  • treatment failure8
  • vomiting8
  • drug eruption7
  • product use in unapproved indication7
  • cough6
  • diarrhoea6
  • fatigue6

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20091
20103
20112
20133
20141
20163
20173
20184
20199
202013
202115
202223
202315
20249
202512
20263

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Panretin (Alitretinoin)

2024 spending

$1.1M

Beneficiaries

69

171 claims

Per beneficiary

$15,280

$98.17 per unit

View as table
YearSpending
2020$0
2021$233,931
2022$1,140,951
2023$965,460
2024$1,054,337

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 42 on PubMed

Sponsor: Advanz Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.